Jorge Cortes, MD, Augusta University, Augusta, GA, gives an overview of the five-year follow-up data from the BFORE trial (NCT02130557), which evaluated the safety and efficacy of bosutinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia (CML). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
